Search Result

Results for "

bone mineralization

" in MedChemExpress (MCE) Product Catalog:

By Targets:	Androgen Receptor (1) Apoptosis (3) Biochemical Assay Reagents (1) CaSR (1) Cathepsin (2) Endogenous Metabolite (2) ERK (2) Fluorescent Dye (1) LDLR (1) MMP (2) NF-κB (1) PCSK9 (1) Phosphatase (3) RAR/RXR (1) RXFP Receptor (1) SARS-CoV (1) Thyroid Hormone Receptor (1) VD/VDR (4)
By Research Areas:	Cancer (9) Cardiovascular Disease (1) Inflammation/Immunology (8) Metabolic Disease (17)

Inhibitors & Agonists

Screening Libraries

Fluorescent Dye

Peptides

Inhibitory Antibodies

Natural
Products

Isotope-Labeled Compounds

Cat. No.	Product Name	Target	Research Areas	Chemical Structure

HY-A0020

Eldecalcitol 2 Publications Verification ED-71; 2-(3-hydroxypropoxy)-1,25-dihydroxyvitamin D3	VD/VDR Apoptosis	Metabolic Disease Inflammation/Immunology Cancer
Eldecalcitol (ED-71) is an orally active vitamin D3 analogue, inhibits bone resorption and increases bone mineral density. Eldecalcitol (ED-71) displays anti-tumor effect and inhibits cell proliferation, migration and induces apoptosis by suppressing GPx-1 .

HY-D0835

Hydroxylapatite (25-45μm) Hydroxyapatite (25-45μm)	Biochemical Assay Reagents	Others
Hydroxylapatite (Hydroxyapatite) is a naturally occurring calcium phosphate which is a major mineral component of bone and teeth bones. Nano-scale Hydroxylapatite particles are increasingly being used as carriers for controlled and targeted delivery of bioactive agents like agents, proteins, and nucleic acids due to their high porosity, negative charge, and biodegradability .

HY-B0657

Clodronic acid Clodronate	Others	Others Cancer
Clodronic acid is an orally active bisphosphonate, which is used for researching osteoporosis and diseases associated with excessive bone resorption. Clodronic acid inhibits bone resorption through induction of osteoclast apoptosis. Clodronic acid is effective in the maintenance or improvement of bone mineral density .

HY-117182

LG190178	Apoptosis VD/VDR RAR/RXR	Metabolic Disease Inflammation/Immunology Cancer
LG190178 is a non-steroidal vitamin D receptor (VDR) ligand that can induce the formation of heterodimer complexes between VDR and retinoid X receptor (RXR), stabilizing the agonistic conformation of the VDR ligand-binding domain and promoting its interaction with co-activators. LG190178 has functions in regulating calcium homeostasis, bone mineralization, as well as cell proliferation, differentiation, and apoptosis, making it useful for research in psoriasis, osteoporosis, and cancer .

HY-A0020R

Eldecalcitol (Standard)	VD/VDR Apoptosis	Metabolic Disease Inflammation/Immunology Cancer
Eldecalcitol (Standard) is the analytical standard of Eldecalcitol. This product is intended for research and analytical applications. Eldecalcitol (ED-71) is an orally active vitamin D3 analogue, inhibits bone resorption and increases bone mineral density. Eldecalcitol (ED-71) displays anti-tumor effect and inhibits cell proliferation, migration and induces apoptosis by suppressing GPx-1 .

HY-P0284

C-telopeptide	MMP	Inflammation/Immunology
C-telopeptide, a cross-linked peptide of type I collagen, is released during bone resorption and has been correlated with bone mineral density (BMD).

HY-103578

S-40503	Androgen Receptor	Cancer
S-40503 is an orally active and selective androgen receptor modulator. S-40503 significantly increases the bone mineral density (BMD) and biomechanical strength of femoral cortical bone .

HY-135702

UBS109	NF-κB	Others
UBS109, as a curcumin analogue, can promote the differentiation and mineralization of osteoblasts. UBS109 shows to regulate bone cell function by activating Smad and inhibiting NF-kB. UBS109 can be used in bone tissue engineering and osteoporosis research .

HY-117817

Ranelic acid	Others	Metabolic Disease
Ranelic acid is an organic acid with metal cation chelating activity. Ranelic acid can be used to inhibit osteoporosis and increase bone mineral density. Ranelic acid derivatives exhibit highly substituted thiophene ring structures .

HY-N8837

Trifloroside	MMP	Metabolic Disease
Trifloroside is a secoiridoid glycoside with antioxidant effects. Trifloroside induces osteogenic effects through osteoblast differentiation, adhesion, migration, and mineral apposition. Trifloroside has the potential for osteoblast-mediated bone diseases research .

HY-153258

CaSR antagonist-1	CaSR	Metabolic Disease
CaSR antagonist-1 is a calcium sensing receptor (CaSR) antagonist with an IC₅₀ value of 50 nM. CaSR antagonist-1 can be used for the research of disorders associated with abnormal bone or mineral homeostasis such as osteoporosis .

HY-D2132

Sulfo-Cy5.5-ALN	Fluorescent Dye	Cancer
Sulfo-Cy5.5-ALN is a fluorescent labeled alendronate, which targets bone. Sulfo-Cy5.5-ALN binds to hydroxyapatite and differentiated osteoblasts in vitro. Sulfo-Cy5.5-ALN selectively binds to the mineralized areas of the tumor. Sulfo-Cy5.5-ALN can be used to detect bone overgrowth in prostate bone metastasis .

HY-P4823

pTH (1-37) (human)	Thyroid Hormone Receptor	Metabolic Disease
pTH (1-37) (human) is a fragment of parathyroid hormone (PTH). pTH (1-37) (human) induces the cAMP formation and increases alkaline phosphatase activity. pTH (1-37) (human) increases growth, bone calcium content, and bone mineral density (BMD) in uremic animals. pTH (1-37) (human) has the potential for the research of osteoporosis .

HY-D0835A

Hydroxylapatite (<50nm) Hydroxyapatite (<50nm)	Others	Cardiovascular Disease Inflammation/Immunology
Hydroxylapatite (<50nm) is a natural form of calcium phosphate and is the main mineral component of bones and teeth. Hydroxylapatite (<50nm) can stimulate the expression and secretion of collagen in primary human dermal fibroblasts. Hydroxylapatite (<50nm) has good biocompatibility, bioactivity, and bone conductivity, making it suitable for targeted drug or nucleic acid delivery. Hydroxylapatite (<50nm) can be used in research on osteoarthritis, gout, and atherosclerosis .

HY-15099

NC 2300 VEL 0230	Cathepsin	Inflammation/Immunology
NC 2300 (VEL-0230)is a selective and orally active cysteine cathepsin inhibitor with the IC₅₀ values of 284, 34.5, and 186 nM for cathepsin B, K, and S, respectively.NC 2300 can be used for study of diseases involving bone mineral disorders .

HY-A0020S

Eldecalcitol-d6	VD/VDR	Metabolic Disease
Eldecalcitol-d₆ is the deuterium labeled Eldecalcitol. Eldecalcitol is an orally active analogue of active vitamin D used in the treatment of osteoporosis.

HY-B2203

Monocalcium glycerophosphate	Phosphatase	Metabolic Disease
Monocalcium glycerophosphate is an inhibitor of intestinal alkaline phosphatase F3, and it has anti-cavity properties. Monocalcium glycerophosphate is a source of calcium and phosphorus in total parenteral nutrition solutions, helps prevent the mineralization and development of bones from intravenous nutrition, and maintains the integrity of the intestinal epithelium .

HY-150186

RXFP2 agonist 2	RXFP Receptor	Metabolic Disease
RXFP2 agonist 2 is a selective，orally active and allosteric RXFP2 agonist with an EC₅₀ value of 0.38 µM. RXFP2 agonist 2 induces osteoblast mineralization. RXFP2 agonist 2 increases bone formation in female mice. RXFP2 agonist 2 has the potential for the research of osteoporosis .

HY-122075

FR 78844	Others	Metabolic Disease
FR 78844 is a potent and orally active bone resorption inhibitor. FR 78844 has the potential for the research of diabetes associated osteopenia .

HY-D0886

β-Glycerophosphate disodium salt pentahydrate Maximum Cited Publications 7 Publications Verification	Phosphatase Endogenous Metabolite ERK	Metabolic Disease Cancer
β-Glycerophosphate disodium salt pentahydrate is a bioactive endogenous metabolite and a phosphatase inhibitor. β-Glycerophosphate disodium salt pentahydrate plays an important role in inducing and maintaining osteoblast differentiation, mineral metabolism and signal transduction, and can be used as a drug carrier to form heat-sensitive hydrogels. β-Glycerophosphate disodium salt hydrate accelerates the calcification of vascular smooth muscle cells .

HY-126304

β-Glycerophosphate disodium salt hydrate Maximum Cited Publications 7 Publications Verification	Phosphatase Endogenous Metabolite ERK	Metabolic Disease
β-Glycerophosphate disodium salt pentahydrate is a bioactive endogenous metabolite and a phosphatase inhibitor. β-Glycerophosphate disodium salt pentahydrate plays an important role in inducing and maintaining osteoblast differentiation, mineral metabolism and signal transduction, and can be used as a drug carrier to form heat-sensitive hydrogels. β-Glycerophosphate disodium salt hydrate accelerates the calcification of vascular smooth muscle cells .

HY-P0059A

Teriparatide acetate hydrate Human parathyroid hormone-(1-34) (acetate hydrate); hPTH (1-34) (acetate hydrate)	Others	Others Cancer
Teriparatide acetate hydrate (Human parathyroid hormone-(1-34) acetate hydrate) is a PTH1 receptor agonist. Teriparatide acetate hydrate (Human parathyroid hormone-(1-34) acetate hydrate) can be used for osteoporosis research .

HY-108044

ONO-5334 2 Publications Verification	Cathepsin SARS-CoV	Metabolic Disease
ONO-5334 is a potent, selective and orally active cathepsin K inhibitor with K_i values of 0.10 nM, 0.049 nM and 0.85 nM for human, rabbit and rat cathepsin K, respectively. ONO 5334 is an effective antiviral compound against SAR-COV-2 virus activity with an EC₅₀ value of 500 nM. ONO-5334 has the potential for the study of osteoporosis and COVID-19 disease .

HY-159595

PCSK9-IN-29	LDLR PCSK9	Metabolic Disease Inflammation/Immunology
PCSK9-IN-29 is a lipid-lowering agent. PCSK9-IN-29 can increase low-density lipoprotein receptor (LDLR) protein expression and decrease PCSK9 protein expression in hepG2 cells. PCSK9-IN-29 can reduce the levels of serum LDL-C, TC, and liver enzyme ALT in crab eating macaques fed a high-fat diet, lower body weight and fat, and increase bone mineral content. PCSK9-IN-29 can be used for research on non-alcoholic fatty liver disease and obesity .

Cat. No.	Product Name

HY-L131

Osteogenesis Compound Library	508 compounds
Ossification is a tightly regulated process, performed by specialized cells called osteoblasts. Dysregulation of this process may cause inadequate or excessive mineralization of bones or ectopic calcification, all of which have grave consequences for human health. Osteoblasts play important roles in the process of osteogenesis and prevention of osteonecrosis. Osteoblast formation and bone formation are regulated by hormones, growth factors, cytokines, etc. MCE offers a unique collection of 508 bone formation compounds with identified and potential inducing osteogenesis activity. MCE bone formation compound library is a useful tool for the study of bone disease drugs and pharmacology.

Osteogenesis Compound Library

508 compounds

Ossification is a tightly regulated process, performed by specialized cells called osteoblasts. Dysregulation of this process may cause inadequate or excessive mineralization of bones or ectopic calcification, all of which have grave consequences for human health.

Osteoblasts play important roles in the process of osteogenesis and prevention of osteonecrosis. Osteoblast formation and bone formation are regulated by hormones, growth factors, cytokines, etc.

MCE offers a unique collection of 508 bone formation compounds with identified and potential inducing osteogenesis activity. MCE bone formation compound library is a useful tool for the study of bone disease drugs and pharmacology.

Cat. No.	Product Name	Type